Celularity Inc. Selling, General and Administrative Expense
Celularity Inc. (CELU) reported Selling, General and Administrative Expense of $51.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-04-30
- Celularity Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $15.06M, a 6.19% decline year-over-year.
- Celularity Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $9.31M, a 26.43% decline year-over-year.
- Celularity Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $12.63M, a 20.58% decline year-over-year.
- Celularity Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $14.26M, a 1.67% increase year-over-year.
- Celularity Inc. selling, general and administrative expense for fiscal 2025 was $51.27M, a 12.58% decline from fiscal 2024.
- Celularity Inc. selling, general and administrative expense for fiscal 2024 was $58.64M, a 15.95% increase from fiscal 2023.
- Celularity Inc. selling, general and administrative expense for fiscal 2023 was $50.58M, a 23.39% decline from fiscal 2022.
- Celularity Inc. selling, general and administrative expense for fiscal 2022 was $66.02M, a 7.46% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $24.37M derived: sum of 2 quarters · filed 2026-04-30 | $37.00M derived: sum of 3 quarters · filed 2026-04-30 | $51.27M 10-K · filed 2026-04-30 |
| 2025-09-30 | $9.31M 10-Q · filed 2025-11-14 | $21.94M derived: sum of 2 quarters · filed 2025-11-14 | $36.20M 10-Q · filed 2025-11-14 | $52.26M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $12.63M 10-Q · filed 2025-08-29 | $26.90M 10-Q · filed 2025-08-29 | $42.95M derived: sum of 3 quarters · filed 2026-04-30 | $55.60M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $14.26M 10-Q · filed 2025-08-29 | $30.32M derived: sum of 2 quarters · filed 2026-04-30 | $42.97M derived: sum of 3 quarters · filed 2026-04-30 | $58.88M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $16.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $28.71M derived: sum of 2 quarters · filed 2026-04-30 | $44.62M derived: sum of 3 quarters · filed 2026-04-30 | $58.64M 10-K · filed 2026-04-30 |
| 2024-09-30 | $12.65M 10-Q · filed 2025-11-14 | $28.56M derived: sum of 2 quarters · filed 2025-11-14 | $42.59M 10-Q · filed 2025-11-14 | $55.65M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $15.91M 10-Q · filed 2025-08-29 | $29.93M 10-Q · filed 2025-08-29 | $43.00M derived: sum of 3 quarters · filed 2025-08-29 | $53.75M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $14.03M 10-Q · filed 2025-08-29 | $27.10M derived: sum of 2 quarters · filed 2025-08-29 | $37.84M derived: sum of 3 quarters · filed 2025-08-29 | $50.67M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $23.82M derived: sum of 2 quarters · filed 2025-05-08 | $36.64M derived: sum of 3 quarters · filed 2025-05-08 | $50.58M 10-K · filed 2025-05-08 |
| 2023-09-30 | $10.75M 10-Q · filed 2024-12-06 | $23.57M derived: sum of 2 quarters · filed 2024-12-06 | $37.51M 10-Q · filed 2024-12-06 | $56.59M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $12.83M 10-Q · filed 2024-11-07 | $26.76M 10-Q · filed 2024-11-07 | $45.84M derived: sum of 3 quarters · filed 2024-11-07 | $60.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $13.93M 10-Q · filed 2024-10-16 | $33.01M derived: sum of 2 quarters · filed 2024-10-16 | $47.92M derived: sum of 3 quarters · filed 2024-10-16 | $63.49M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $19.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $33.99M derived: sum of 2 quarters · filed 2024-07-30 | $49.56M derived: sum of 3 quarters · filed 2024-07-30 | $66.02M 10-K · filed 2024-07-30 |
| 2022-09-30 | $14.91M 10-Q · filed 2024-01-03 | $30.48M derived: sum of 2 quarters · filed 2024-01-03 | $46.94M 10-Q · filed 2024-01-03 | $60.15M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $15.57M 10-Q · filed 2023-08-14 | $32.03M 10-Q · filed 2023-08-14 | $45.24M derived: sum of 3 quarters · filed 2023-08-14 | $66.89M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $16.46M 10-Q · filed 2023-05-22 | $29.67M derived: sum of 2 quarters · filed 2023-05-22 | $51.31M derived: sum of 3 quarters · filed 2023-05-22 | $80.17M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $34.85M derived: sum of 2 quarters · filed 2023-03-31 | $63.72M derived: sum of 3 quarters · filed 2023-03-31 | $71.34M 10-K · filed 2023-03-31 |
| 2021-09-30 | $21.64M 10-Q · filed 2022-11-10 | $50.51M derived: sum of 2 quarters · filed 2022-11-10 | $58.13M 10-Q · filed 2022-11-10 | $64.11M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $28.86M 10-Q · filed 2022-08-09 | $36.49M 10-Q · filed 2022-08-09 | $42.46M derived: sum of 3 quarters · filed 2022-08-09 | $50.79M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $7.63M 10-Q · filed 2022-05-16 | $13.60M derived: sum of 2 quarters · filed 2022-05-16 | $21.93M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $14.30M derived: sum of 2 quarters · filed 2022-03-31 | $31.34M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $8.33M 10-Q · filed 2021-11-12 | $25.36M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |